



Survey

Paediatric antiviral drug use and potential adverse reactions

The 2009 influenza A (H1N1) virus has reached pandemic level, also affecting the paediatric population. In this context, Health Canada issued an interim approval for the emergency use of oseltamivir in children under one year of age,* given their increased risk for morbidity and mortality from influenza.



Health Canada has commissioned this survey to assess if any **serious and life-threatening adverse reactions (ARs)**† are occurring with the use of antiviral drugs in Canadian children and youth.

Your contribution is greatly appreciated.

Over the past month:

1. Have you prescribed the antiviral drugs oseltamivir (Tamiflu™) or zanamivir (Relenza™) to any patients **<18 years**?
 Yes ___ No ___ **If no, please proceed to question 3.**
 If yes, to how many paediatric patients?
 oseltamivir: 1–3 ___ 4–6 ___ 7–9 ___ ≥10 ___ approximate number ___
 zanamivir: 1–3 ___ 4–6 ___ 7–9 ___ ≥10 ___ approximate number ___

2. Have you prescribed oseltamivir (Tamiflu™) to any **infants <1 year**? Yes ___ No ___
 If yes, to how many? 1 ___ 2 ___ 3 ___ 4 ___ ≥5 ___ approximate number ___

3. Have you seen any serious ARs that you suspect may be related to the use of **oseltamivir (Tamiflu™)**? Yes ___ No ___
 If yes:
In patients <1 year
 Number of patients 1 ___ 2 ___ 3 ___ 4 ___ ≥5 ___ approximate number ___
 Number of serious ARs 1 ___ 2 ___ 3 ___ 4 ___ ≥5 ___ approximate number ___
 List ARs _____

If yes:
In patients 1-18 years of age
 Number of patients 1 ___ 2 ___ 3 ___ 4 ___ ≥5 ___ approximate number ___
 Number of serious ARs 1 ___ 2 ___ 3 ___ 4 ___ ≥5 ___ approximate number ___
 List ARs _____

4. Have you seen any serious ARs that you suspect may be related to the use of **zanamivir (Relenza™)**? Yes ___ No ___
 If yes:
 Number of patients 1 ___ 2 ___ 3 ___ 4 ___ ≥5 ___ approximate number ___
 Number of serious ARs 1 ___ 2 ___ 3 ___ 4 ___ ≥5 ___ approximate number ___
 List ARs _____

* www.phac-aspc.gc.ca/alert-alerte/h1n1/guidance-orientation-07-20-eng.php

† A serious and life-threatening adverse reaction is one that results in emergency observation, hospitalisation, persistent or significant disability or death.

**Please return this survey with your monthly reporting form.
 Thank you for your participation.**